Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma

[1]  L. Kwak,et al.  Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine , 2001, Journal of Cancer Research and Clinical Oncology.

[2]  M. C. Popescu,et al.  Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen , 2004, Clinical Cancer Research.

[3]  E. Yvon,et al.  Antigen-induced regulatory T cells. , 2004, Blood.

[4]  B. Hennessy,et al.  Non-Hodgkin lymphoma: an update. , 2004, The Lancet. Oncology.

[5]  S. Rosenberg.  Development of effective immunotherapy for the treatment of patients with cancer. , 2004, Journal of the American College of Surgeons.

[6]  M. Baseler,et al.  A modified human ELISPOT assay to detect specific responses to primary tumor cell targets , 2004, Journal of Translational Medicine.

[7]  R. Pierson,et al.  Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. , 2003, Transplant immunology.

[8]  W. Wilson,et al.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. , 2003, Blood.

[9]  R. Ahmed,et al.  A Specific Role for B Cells in the Generation of CD8 T Cell Memory by Recombinant Listeria monocytogenes 1 , 2003, The Journal of Immunology.

[10]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[11]  A. Plebani,et al.  Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia. , 2002, Blood.

[12]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[13]  W. Wilson,et al.  The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. , 2002, Seminars in oncology.

[14]  C. Kneitz,et al.  Effective B cell depletion with rituximab in the treatment of autoimmune diseases. , 2002, Immunobiology.

[15]  L. Kwak,et al.  Novel Secondary Ig VH Gene Rearrangement and In-Frame Ig Heavy Chain Complementarity-Determining Region III Insertion/Deletion Variants in De Novo Follicular Lymphoma1 , 2001, The Journal of Immunology.

[16]  L. Bradley,et al.  A Critical Role for B Cells in the Development of Memory CD4 Cells1 2 , 2000, The Journal of Immunology.

[17]  J. Larsen,et al.  Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. , 2000, Blood.

[18]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[19]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Heath,et al.  B Cells Directly Tolerize CD8+ T Cells , 1998, The Journal of experimental medicine.

[21]  R. Brunham,et al.  Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. , 1998, Journal of immunology.

[22]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[23]  R. Förster,et al.  Analyzing cytotoxic T lymphocyte activity: a simple and reliable flow cytometry-based assay. , 1997, Journal of immunological methods.

[24]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Gribben,et al.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Duffey,et al.  Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor , 1995, The Lancet.

[27]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[28]  D. Parker,et al.  Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens , 1992, The Journal of experimental medicine.

[29]  T. Gajewski,et al.  Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. , 1991, Journal of immunology.

[30]  W. Carroll,et al.  Mouse x human heterohybridomas as fusion partners with human B cell tumors. , 1986, Journal of immunological methods.

[31]  K. Johnson.  An Update. , 1984, Journal of food protection.